Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy

Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GBMs. In spite of various RTKs being mutated or altered in the majority of GBMs, clinical studies h...

Exploration of Receptor Tyrosine Kinase Inhibitor for Molecular Targeting Therapy

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.

BACKGROUND Sarcomas are rare mesenchymally derived tumors for which there are limited treatment options. This paper discusses the current therapeutic potential of directed tyrosine kinase inhibitors (TKIs) in sarcoma. METHODS The authors review antibody-based strategies and small molecular inhibitors of TKIs, with specific emphasis placed on the potential use of these targeted agents as thera...

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

The remarkable progress made in the treatment of chronic myeloid leukemia (CML) over the past decade has been accompanied by steady improvements in our capacity to accurately and sensitively monitor response to therapy. After the initial target of therapy, complete cytogenetic response (CCR), is achieved, peripheral blood BCR-ABL transcript levels measured by real-time quantitative reverse tran...

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

BACKGROUND Research into chronic myeloid leukemia (CML) is increasingly focused on the problem of imatinib failure. Dasatinib and nilotinib are both active in chronic- and accelerated-phase CML, including patients with imatinib-resistant or intolerant disease. METHODS This paper reviews advances in tailoring tyrosine kinase inhibition therapy according to patient risk profiles as well as hema...